Global drugmakers slash investments and payments into Russia

23 August 2022

Global drugmakers have significantly reduced their investments and payments into Russia and its pharmaceutical market this year due to the ongoing military conflict between Ukraine and Russia and sanctions imposed on the latter, reports The Pharma Letter’s local correspondent.

After February 24, 2022, the majority of Western pharmaceutical companies have drastically reduced their payments to Russian doctors as well as industry associations, and have significantly limited the provision of various grants and marketing promotion of their drugs.

Prior to the war, among the biggest spenders on these activities in Russia were Merck & Co (NYSE: MRK) and Bayer (BAYN: DE), as well as AstraZeneca (LSE: AZN), according to some analysts, however, most of these companies will probably cut their budgets for Russia for the current year. This is desp Saveite the fact that most of these companies continue the supplies of their drugs to Russia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK